Ms Alyson Evans
I joined the University of Sheffield in 1997, as a Research Technician in the Department of Pathology. Prior to that, I worked at the Tenovus Institute for Cancer Research in Cardiff, then Hope Hospital Biochemistry lab, Salford followed by the Paterson Institute at the Christie Hospital Manchester. I have been the Lead Technician in the Breast Cancer team in the Academic Unit of Clinical Oncology since 2001.
During my career, I have gained a broad experience of techniques including cell culture, immunohistochemistry, histology and molecular biology. My responsibilities include training of all new team members in a range of techniques, practical supervision of new students, development of new assays, sample collection/logging and storage, COSHH compliance, data analysis and manage the day to day running of the group. I also liaise with other technical staff to ensure coordinated sharing of technical skills and good practice.
I work in a team that is focused on tumour-induced bone disease in breast cancer and in particular the molecular mechanisms involved in tumour cell - bone interactions and how these can be targeted by anti-cancer therapies. Working closely with academics and students, I have contributed to a number of scientific publications in this field.
I am a STEM Ambassador, promoting science in schools, and together with other Ambassadors, I have been involved in Bone Workshops for children at Primary schools. I have also organised Bone Biology workshops for new staff and students with the department.
Examples of My staining of Histological Sections and Cells.
- Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P, Ottewell PD (2015). Human breast cancer bone metastasis in vitro and in vivo – a novel 3D model system for studies of tumour cell-bone cell interactions. Clin Exp Mets. 32(7):689-702
- Talari ACS, Evans CA, Holen I, Coleman RE, Rheman I U (2015). Raman spectroscopy of different subtypes of breast cancer cell lines. Journal of Raman Spectroscopy Doi: 10.1002/jrs.4676
- Nutter FN, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE, Ottewell PD (2014). Different molecular profiles are associated with breast cancer cell homing compared to colonisation of bone – evidence using a novel bone-seeking cell line. Endocrine Related Cancer, 21(2):327-41
- Winter CM, Wilson C, Syddall SP, Cross SS, Evans CA, Ingram CE, Jolley IJ, Hatton MQ, Freeman J, Mori S, Holen I and Coleman RE (2013). Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer – a randomised biomarker evaluation. Clinical Cancer Res. 19(10):2755-65.
- Brown HK, Ottewell PD, Evans CA, Coleman RE, Holen I (2012). A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblast and osteoclasts. Journal of Bone Oncology, 1:47-56.
- Holen I, Whitworth J, Nutter F, Evans CA, Brown HK, Barbaric I, Jones M, Ottewell PD (2012). Loss of plakoglobin promotes decreased cell-cell contact, increased invasion and breast cancer cell dissemination in vivo. Breast Cancer Res. 14(3):R86
- Brown HK, Ottewell PD, Evans CA, Holen I (2012). Location matters - osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clinical and Experimental Metastasis, (8):927-38.
- Michailidou M, Brown NJ, Brown HK, Lefley DV, Evans CA, Cross SS, Coleman RE, Holen I (2010). Modulation of endothelial cells by zoledronic acid and paclitaxel in vitro and in vivo: a potential anti-angiogenic strategy. J VAsc Res, 47:481-493.
- Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I (2010). Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model Int J Cancer, 126(2) 522-532.
- Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I (2009). Anti-cancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumour growth in bone. Molecular Cancer Therapeutics 8(10)2821-32.
- Clyburn RD, Reid P, Evans CA, Lefley DV and Holen I (2009). Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro – supporting the benefits of combination therapy. Chemotherapy and Pharmacology 65(5):969-78.
- Mönkkönen H, Kuokkanen J, Holen I, Evans CA, Lefley DV, Jauhiainen M, Auriola S Mönkkönen J (2008) Bisphosphonate –induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs, 19(4)391-399.
- Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR, Holen I (2006). The expression of receptor activator of nuclear factor kappa beta ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in breast cancer and their relationships with osteoprotegerin (OPG), oestrogen receptor (ER) and clinicopathological parameters J Clin Pathol 59(1) 56-63
- Neville-Webbe HL, Evans CA, Coleman RE, Holen I (2006). Mechanisms of the synergistic interaction between the bisphosphonate Zoledronic Acid and the chemotherapy agents Paclitaxel in breast cancer cells in vitro. Tumor Biology 27:92-103.
- Cross SS, Yang Z, Brown NJ, P Balasubramanian SP, Evans CA, Woodward JKL, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE, Holen I (2005). Osteoprotegerin (OPG) – a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118 (8)1901-1908
- Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL (2005). Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo – a role in tumour cell survival? Breast Cancer Research and Treatment 92;207-215.
- Neville-Webbe HL, Rostami-Hodjegan A, Evans CA Coleman RE, Holen I (2005). Sequence- and Schedule-Dependent Enhancement of Zoledronic Acid Induced Apoptosis by Doxorubicin in Breast and Prostate Cancer Cells, Int J Cancer 113(3)364-371
- Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I (2004). Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis Breast Cancer Research and Treatment, 86;269-279.